Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain.

Fresquet M, Rhoden SJ, Jowitt TA, McKenzie EA, Roberts I, Lennon R, Brenchley PE.

J Autoimmun. 2019 Aug 5:102308. doi: 10.1016/j.jaut.2019.102308. [Epub ahead of print]

2.

PLA2R binds to the annexin A2-S100A10 complex in human podocytes.

Fresquet M, Jowitt TA, McKenzie EA, Ball MD, Randles MJ, Lennon R, Brenchley PE.

Sci Rep. 2017 Jul 31;7(1):6876. doi: 10.1038/s41598-017-07028-8.

3.

Membranous nephropathy: integrating basic science into improved clinical management.

Cattran DC, Brenchley PE.

Kidney Int. 2017 Mar;91(3):566-574. doi: 10.1016/j.kint.2016.09.048. Epub 2017 Jan 5. Review.

PMID:
28065518
4.

Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.

Kanigicherla DAK, Hamilton P, Czapla K, Brenchley PE.

Nephrology (Carlton). 2018 Jan;23(1):60-68. doi: 10.1111/nep.12955.

PMID:
27778424
5.

Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.

Kanigicherla DA, Short CD, Roberts SA, Hamilton P, Nikam M, Harris S, Brenchley PE, Venning MC.

Nephrol Dial Transplant. 2016 Dec;31(12):2108-2114. Epub 2016 Jan 13.

PMID:
26769682
6.

Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.

Brenchley PE.

J Am Soc Nephrol. 2015 Oct;26(10):2308-11. doi: 10.1681/ASN.2015020181. Epub 2015 Mar 24. No abstract available.

7.

rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial.

Coupes B, de Freitas DG, Roberts SA, Read I, Riad H, Brenchley PE, Picton ML.

BMC Res Notes. 2015 Feb 3;8:21. doi: 10.1186/s13104-014-0964-0.

8.

Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer.

Simmons SC, Jämsä H, Silva D, Cortez CM, McKenzie EA, Bitu CC, Salo S, Nurmenniemi S, Nyberg P, Risteli J, deAlmeida CE, Brenchley PE, Salo T, Missailidis S.

PLoS One. 2014 Oct 8;9(10):e96846. doi: 10.1371/journal.pone.0096846. eCollection 2014.

9.

Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.

Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, Lennon R, Brenchley PE.

J Am Soc Nephrol. 2015 Feb;26(2):302-13. doi: 10.1681/ASN.2014050502. Epub 2014 Oct 6.

10.

Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.

Bech AP, Hofstra JM, Brenchley PE, Wetzels JF.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1386-92. doi: 10.2215/CJN.10471013. Epub 2014 Jul 17.

11.

The genetic contribution to recurrent autoimmune nephritis.

Brenchley PE, Poulton K, Morton M, Picton ML.

Transplant Rev (Orlando). 2014 Jul;28(3):140-4. doi: 10.1016/j.trre.2014.01.004. Epub 2014 Jan 27. Review.

PMID:
24630158
12.

Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis.

Pajek J, Hutchison AJ, Bhutani S, Brenchley PE, Hurst H, Perme MP, Summers AM, Vardhan A.

Perit Dial Int. 2014 May;34(3):289-98. doi: 10.3747/pdi.2012.00248. Epub 2014 Feb 4.

13.

Global analysis reveals the complexity of the human glomerular extracellular matrix.

Lennon R, Byron A, Humphries JD, Randles MJ, Carisey A, Murphy S, Knight D, Brenchley PE, Zent R, Humphries MJ.

J Am Soc Nephrol. 2014 May;25(5):939-51. doi: 10.1681/ASN.2013030233. Epub 2014 Jan 16.

14.

The role of mouse strain differences in the susceptibility to fibrosis: a systematic review.

Walkin L, Herrick SE, Summers A, Brenchley PE, Hoff CM, Korstanje R, Margetts PJ.

Fibrogenesis Tissue Repair. 2013 Sep 25;6(1):18. doi: 10.1186/1755-1536-6-18.

15.

Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P.

J Am Soc Nephrol. 2013 Mar;24(4):677-83. doi: 10.1681/ASN.2012070730. Epub 2013 Feb 21.

16.

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE.

Kidney Int. 2013 May;83(5):940-8. doi: 10.1038/ki.2012.486. Epub 2013 Jan 30.

17.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF.

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. Epub 2012 Sep 6.

18.

Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1).

Simmons SC, McKenzie EA, Harris LK, Aplin JD, Brenchley PE, Velasco-Garcia MN, Missailidis S.

PLoS One. 2012;7(6):e37938. doi: 10.1371/journal.pone.0037938. Epub 2012 Jun 15. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/48b14416-bb2e-422f-89db-cf7f81df61aa.

19.

Pharmacology, efficacy and safety of oral phosphate binders.

Hutchison AJ, Smith CP, Brenchley PE.

Nat Rev Nephrol. 2011 Sep 6;7(10):578-89. doi: 10.1038/nrneph.2011.112. Review.

PMID:
21894188
20.

A collaborative approach to understanding EPS: the European perspective.

Summers AM, Abrahams AC, Alscher MD, Betjes M, Boeschoten EW, Braun N, Brenchley PE, Davies S, Dunn L, Engelsman L, Fieren M, Garosi G, Goffin E, Heuveling L, Korte M, Lindholm B, Rutherford P, Struijk D, Verduijn M, Verger C, Westerhuis R.

Perit Dial Int. 2011 May-Jun;31(3):245-8. doi: 10.3747/pdi.2010.00086. Review. No abstract available.

PMID:
21555409
21.

Encapsulating peritoneal sclerosis following renal transplantation despite tamoxifen and immunosuppressive therapy.

de Freitas D, Augustine T, Hurst H, Taylor P, Williams R, Hutchison A, Brenchley PE, Summers AM.

NDT Plus. 2008 Oct;1(5):333-5. doi: 10.1093/ndtplus/sfn109. Epub 2008 Aug 8.

22.

Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis.

de Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, Hutchison A, Brenchley PE, Augustine T, Summers AM.

Perit Dial Int. 2008 May-Jun;28(3):271-6.

PMID:
18474920
23.

VEGF polymorphisms are associated with severity of diabetic retinopathy.

Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, Ray DW.

Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3611-6. doi: 10.1167/iovs.07-1383. Epub 2008 Apr 25.

PMID:
18441306
24.

Trophoblast-derived heparanase is not required for invasion.

Harris LK, Baker PN, Brenchley PE, Aplin JD.

Placenta. 2008 Apr;29(4):332-7. doi: 10.1016/j.placenta.2008.01.012. Epub 2008 Mar 10.

PMID:
18329709
25.

Development and functional capacity of transplanted rat metanephroi.

Dilworth MR, Clancy MJ, Marshall D, Bravery CA, Brenchley PE, Ashton N.

Nephrol Dial Transplant. 2008 Mar;23(3):871-9. Epub 2007 Oct 12.

PMID:
17933838
26.

TGF-beta1 in chronic allograft nephropathy following renal transplantation.

Harris S, Coupes BM, Roberts SA, Roberts IS, Short CD, Brenchley PE.

J Nephrol. 2007 Mar-Apr;20(2):177-85.

PMID:
17514622
27.

Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.

Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R, Jayson GC.

Cancer Sci. 2007 Jun;98(6):844-9. Epub 2007 Apr 5.

28.

The emergence of networks in human genome epidemiology: challenges and opportunities.

Seminara D, Khoury MJ, O'Brien TR, Manolio T, Gwinn ML, Little J, Higgins JP, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam AP, Danesh J, Davey Smith G, Dolan S, Duncan R, Gruis NA, Hashibe M, Hunter D, Jarvelin MR, Malmer B, Maraganore DM, Newton-Bishop JA, Riboli E, Salanti G, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Ioannidis JP; Human Genome Epidemiology Network; Network of Investigator Networks.

Epidemiology. 2007 Jan;18(1):1-8. No abstract available.

PMID:
17179752
29.

Malnutrition and refeeding syndrome associated with encapsulating peritoneal sclerosis.

Jordaan A, de Freitas DG, Hurst H, Alderdice J, Curwell J, Brenchley PE, Hutchison AJ, Summers AM.

Perit Dial Int. 2007 Jan-Feb;27(1):100-1. No abstract available.

PMID:
17179524
30.

Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy.

Kovács TJ, Harris S, Vas TK, Seres I, Short CD, Wittmann IK, Paragh G, Mackness MI, Mackness B, Durrington PN, Nagy JM, Brenchley PE.

J Nephrol. 2006 Nov-Dec;19(6):732-8.

PMID:
17173245
31.

An international encapsulating peritoneal sclerosis registry and DNA bank: why we need one now.

Summers AM, Brenchley PE.

Perit Dial Int. 2006 Sep-Oct;26(5):559-63. Review. No abstract available.

PMID:
16973509
32.

Translating knowledge of the human genome into clinical practice in nephrology dialysis and transplantation: the renal genome network (ReGeNet).

Brenchley PE, Lindholm B, Dekker FW, Navis G.

Nephrol Dial Transplant. 2006 Oct;21(10):2681-3. Epub 2006 Aug 25. No abstract available.

PMID:
16935905
33.

Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus.

Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE.

Arthritis Res Ther. 2006;8(3):R81. Epub 2006 Apr 28.

34.

A road map for efficient and reliable human genome epidemiology.

Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam A, Danesh J, Smith GD, Dolan S, Duncan R, Gruis NA, Hartge P, Hashibe M, Hunter DJ, Jarvelin MR, Malmer B, Maraganore DM, Newton-Bishop JA, O'Brien TR, Petersen G, Riboli E, Salanti G, Seminara D, Smeeth L, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Khoury MJ; Human Genome Epidemiology Network and the Network of Investigator Networks.

Nat Genet. 2006 Jan;38(1):3-5.

PMID:
16468121
35.

Association between ICAM-1 Gly-Arg polymorphism and renal parenchymal scarring following childhood urinary tract infection.

Gbadegesin RA, Cotton SA, Watson CJ, Brenchley PE, Webb NJ.

Int J Immunogenet. 2006 Feb;33(1):49-53.

PMID:
16426244
36.

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE.

J Invest Dermatol. 2006 Feb;126(2):453-9.

37.

Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.

Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, Riad H, Hutchison AJ, Taylor P, Pearson R, Gokal R.

Kidney Int. 2005 Nov;68(5):2381-8.

38.

VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5.

Summers AM, Coupes BM, Brennan MF, Ralph SA, Short CD, Brenchley PE.

Nephrol Dial Transplant. 2005 Nov;20(11):2427-32. Epub 2005 Jul 26.

PMID:
16046504
39.

Plasmodium falciparum malaria in south-west Nigerian children: is the polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria?

Amodu OK, Gbadegesin RA, Ralph SA, Adeyemo AA, Brenchley PE, Ayoola OO, Orimadegun AE, Akinsola AK, Olumese PE, Omotade OO.

Acta Trop. 2005 Sep;95(3):248-55.

PMID:
16002039
40.

Transplantation of metanephroi to sites within the abdominal cavity.

Marshall D, Clancy M, Bottomley M, Symonds K, Brenchley PE, Bravery CA.

Transplant Proc. 2005 Jan-Feb;37(1):194-7.

PMID:
15808591
41.

Heparanase activity is dysregulated in children with steroid-sensitive nephrotic syndrome.

Holt RC, Webb NJ, Ralph S, Davies J, Short CD, Brenchley PE.

Kidney Int. 2005 Jan;67(1):122-9.

42.

Angiogenic cytokines in patients with idiopathic interstitial pneumonia.

Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ.

Thorax. 2004 Jul;59(7):581-5.

43.

Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies.

He X, Brenchley PE, Jayson GC, Hampson L, Davies J, Hampson IN.

Cancer Res. 2004 Jun 1;64(11):3928-33.

44.

Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.

Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE.

J Invest Dermatol. 2004 Jan;122(1):209-15.

45.

Cytokines and cell adhesion molecules in the inflammatory response during acute pyelonephritis.

Webb NJ, Brenchley PE.

Nephron Exp Nephrol. 2004;96(1):e1-6. Review.

PMID:
14752242
46.

Vascular permeability factors in steroid-sensitive nephrotic syndrome and focal segmental glomerulosclerosis.

Brenchley PE.

Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi21-5. Review.

PMID:
12953037
47.

A multiwell format assay for heparanase.

Behzad F, Brenchley PE.

Anal Biochem. 2003 Sep 15;320(2):207-13.

PMID:
12927826
48.

Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy.

Cattran DC, Wald R, Brenchley PE, Coupes B; North American Nephrotic Syndrome Group; Genes, Gender and Glomerulonephritis Group.

Clin Nephrol. 2003 Jul;60(1):7-12. No abstract available.

PMID:
12872852
49.

Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.

Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW.

Cancer Res. 2003 Feb 15;63(4):812-6.

50.

Steroid-sensitive nephrotic syndrome and vascular endothelial growth factor gene polymorphisms.

Holt RC, Ralph SA, Webb NJ, Watson CJ, Clark AG, Mathieson PW, Brenchley PE.

Eur J Immunogenet. 2003 Feb;30(1):1-3.

PMID:
12558813

Supplemental Content

Loading ...
Support Center